ESR1 and breast carcinoma: The TAMRAD study similarly evaluated the use of tamoxifen +/− everolimus for the treatment of advanced, anti-estrogen-resistant ER+ breast cancer; patients in the combination arm experienced a prolonged time-to-progression compared to tamoxifen/placebo (8.6 vs. 4.5 months), and a 55% reduction in risk of death [9].